Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) announced new clinical findings (April 9, 2026) showing the PureWick® Urine Collection System helped women with nighttime urinary incontinence report better sleep, greater comfort, and ease of use.
In a four-week randomized trial of 165 women across 13 U.S. sites, ~70% said they would continue using PureWick®; study noted low skin irritation and effective urine capture.
BD (NYSE:BDX) announced CE Marking for the Liverty™ TIPS Stent Graft, an adjustable‑diameter device (6–10 mm) designed to treat portal hypertension complications across the EU. Safety and effectiveness data from the pivotal ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Meeting on April 12, 2026.
The device offers a broad range of covered TIPS stent lengths, a flexible nitinol frame, dual‑layer ePTFE encapsulation, and a triaxial delivery system. In the U.S. the device remains investigational.
BD (NYSE: BDX) on April 7, 2026 launched the HemoSphere Stream™ Module, a compact device that streams continuous, noninvasive beat-to-beat arterial waveform data to compatible multiparameter bedside monitors.
Used with the VitaWave™ Plus Finger Cuff, it forms the VitaWave™ Plus System, validated against arterial line measurements and designed to broaden continuous blood pressure monitoring across care settings.
BD (NYSE: BDX) announced the European launch of the BD Pyxis Pro Dispensing Solution and the BD Incada Connected Care Platform on April 1, 2026.
The systems combine advanced automation, AI-driven analytics and connected data to improve medication inventory control, security (RFID, barcode, illuminated bins), refrigerated-to-ambient storage capacity and clinician efficiency. The Pyxis Pro will roll out across Europe with support for 15 languages, and BD plans to extend BD Incada Analytics to European hospitals next year using the AWS European Sovereign Cloud.
BD (NYSE: BDX) received FDA 510(k) clearance on March 2, 2026 for Surgiphor™ 1000mL, the first 1000 mL antimicrobial irrigation system designed for powered lavage. Surgiphor™ 1000mL is terminally sterile, ready-to-use, and built to integrate with common powered lavage devices to standardize wound irrigation and improve OR efficiency.
Key features include a powered-device adapter, Y-connector for quick switching, optimized flow with integrated venting, and a collapsible bottle for handling and evacuation.
Becton, Dickinson and Company (NYSE: BDX) announced pricing and accepted amounts for previously announced tender offers to purchase up to $2,000,000,000 aggregate principal amount (the Aggregate Offer Cap) of multiple series of its senior notes.
The company set Total Consideration per $1,000 for each series, will settle early on February 27, 2026 for early tenders, and allocated accepted principal by series (notable acceptances include $656,047,000 of 4.669% notes, $472,349,000 of 4.685% notes, $444,588,000 of 5.081% notes and $262,727,000 of 3.794% notes).
Becton, Dickinson and Company (NYSE: BDX) announced early tender results and an upsizing of its tender offers. The company increased the Aggregate Offer Cap from $1,600,000,000 to $2,000,000,000 and raised the Offer SubCap for its 4.685% Senior Notes due 2044. Withdrawal rights expired Feb 24, 2026; the company elected an Early Settlement Date of Feb 27, 2026. Securities accepted for purchase will be retired and cancelled. Total consideration will be determined by fixed spreads plus Treasury yields at 10:00 a.m. ET on Feb 25, 2026.
BD (NYSE: BDX) will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026 at 8:30 a.m. ET. The presentation will be webcast live and a replay will be posted on BD's investor relations website, investors.bd.com.
BD (NYSE: BDX) announced the BD Vacutainer® Urine Complete Cup Kit on February 23, 2026, a three-tube urine collection system designed to preserve specimen integrity, reduce repeat collections, and streamline testing workflows.
The kit includes culture, urinalysis, and discard tubes, a sterile cup with integrated transfer device, and a Castile wipe. Available in the United States with Hemogard and conventional stoppers and compatible with automated workflows; orders available through local sales representatives.
BD (NYSE: BDX) named Lanesha Minnix executive vice president and general counsel, effective March 16, 2026. Minnix will lead the Law Group and Public Affairs, report to Tom Polen, and join the BD Executive Leadership Team. She joins from Walgreens Boots Alliance, where she helped lead a $24 billion take-private transaction and oversaw legal, corporate affairs, risk, security and EHS. Minnix previously held senior roles at Ecolab and Flowserve and holds a JD and MBA from the University of Tulsa and a BS in Business Administration from Saint Louis University.